Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis

NCT06080789 is registered in ClinicalTrials.gov with Panafina, Inc. as lead sponsor.

NCT NCT06080789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06080789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis
Lead sponsor
Panafina, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 28, 2024
Completion date
December 31, 2026
Enrollment
36 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute pancreatitis